menu toggle

Precision Medicine Testing Recommendations For: 

Renal Cell Carcinoma

Renal Cell Carcinoma (RCC) - Genetic Risk 

Renal Cell Carcinoma (RCC) - Genetic Risk

 

 

Who should be tested?

  • Genetic testing is recommended for those with a hereditary renal cell carcinoma syndrome based on any of the following:    
  • 1st or 2nd degree relative with RCC diagnosis  
  • Diagnosed ≤46 years old 
  • Bilateral or multifocal tumors
  • Multifocal papillary histology
  • HLRSS-associated RCC, RCC with Fumarate hydrtas (FH) deficiency
  • BHDS related histology (multiple chromophobe, oncocytoma, oncocytic hybrid)
  • Angiomyolipomas of the kidney and one TSC criterion in same person     
  • Succinate dehydrogenase (SDH) deficient RCC histologytment eligible

When and what should be tested?

  • Upon or before presentation
  • Peripheral blood, saliva or buccal mucosa swab

What tests should be considered?

  • NCCN/FDA Approved
    • BAP1
    • FLCN
    • FH
    • MET
    • SDHA/B/C/D
    • TSC1, TSC2
    • VHL
*Ensure inclusion into the molecularly targeted set of testing recommendations